Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Author's Avatar
Nov 08, 2021

Gossamer+Bio%2C+Inc.(Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the third quarter of 2021 and provided a corporate update.